SureTrader Advertisement SureTrader
Home > Boards > US OTC > Medical - Drugs >

Elite Pharmaceuticals (ELTP)

Add ELTP Price Alert      Hide Sticky   Hide Intro
Moderator: Mocha Jet, Drugdoctor, lasers, John_Langston, IB_, sitten-bull
Search This Board:
Last Post: 5/2/2016 3:21:45 AM - Followers: 741 - Board type: Free - Posts Today: 9

Elite Pharmaceuticals is a specialty pharmaceutical company specializing in niche generics and committed to the development of abuse-deterrent opioids to help curb diversion, misuse and abuse.  Elite has a pipeline of opioid abuse-deterrent products under development utilizing the company’s proprietary pharmacological abuse-deterrent technology.

Elite’s website can be found by going to

How ART Works:

Elite’s proprietary abuse-deterrent technology, ART™, is a multi-particulate capsule which contains an opioid agonist in addition to naltrexone, an opioid antagonist used primarily in the management of alcohol dependence and opioid dependence. When this product is taken as intended, the naltrexone is designed to pass through the body unreleased while the opioid agonist releases over time providing therapeutic pain relief for which it is prescribed. If the multi-particulate beads are crushed or dissolved, the opioid antagonist, naltrexone, is designed to release. The absorption of the naltrexone is intended to block the euphoria by preferentially binding to same receptors in the brain as the opioid agonist and thereby reducing the incentive for abuse or misuse by recreational drug abusers. Elite’s pharmacological approach to abuse-deterrence can be applied to a wide range of opioids used today in pain management.


Recent Press Releases:

Oct 21, 2015
Elite Pharmaceuticals Announces Positive Top-Line Results From a Pivotal Phase 3 Study for Abuse-Deterrent Opioid ELI-200

Aug 10, 2015
Elite Pharmaceuticals Reports Record Revenues for First Quarter of Fiscal Year 2016

Aug 3, 2015
Elite Pharmaceuticals Completes Enrollment and Dosing for ELI-200 Phase III Efficacy Trial

Jun 16, 2015
Elite Pharmaceuticals Granted New Patent for Abuse Deterrent Technology

Jun 9, 2015
Elite Pharmaceuticals and Epic Pharma Enter Into a Sales and Distribution Licensing Agreement for Abuse-Deterrent ELI-200

More information can be found by going to Elite’s investor section:
Highlights From Last Quarter:
Second quarter ending September, 2015
Consolidated revenues for the second quarter of fiscal 2015 was $2.7M, all of which came from Elite's generic operation. An increases of 30% over last quarter's generic revenues. Generic revenue continues to grow with new highs being set  8 out of the 10 last quarters. The cost of revenue for this quarter totals $1.4M, for a gross profit of $1.3M. Overall expenses for the quarter total $5.3M with $4.2M going towards the development of Elite’s proprietary abuse-deterrent opioid product,ELI-200.
Business Update
The first product to utilize Elite's abuse deterrent technology, ELI-200, has successfully completed Phase III studies. The Company believes that it will be able to file a New Drug Application (NDA) with the FDA during this calendar year. When this application is accepted by the FDA it will be granted expedited review by the FDA,the company estimates that approval could be achieved in calender Q2\2016. Shareholders will be notified when the FDA accepts the ELI-200 NDA which is estimated to be in the first or second week in Jan, 2016.
Common shares issued pursuant to the strategic alliance agreement with Epic Investments LLC.
As per the Epic Strategic Alliance, Elite is entitled to 15% of the profits achieved from the commercial sales of Epic's immediate release oxycodone tablets, for a 10 year period commencing on the date of first commercial shipment and Epic is to receive 3 million shares of Common Stock upon approval by the FDA of the ANDA.




President & Chief Executive Officer - Nasrat Hakim

Nasrat Hakim joined Elite in August 2013 as Director, President and Chief Executive Officer. Mr. Hakim has more than 30 years of pharmaceutical and medical industry experience in Quality Assurance, Analytical Research and Development, Technical Services and Regulatory Compliance. He brings with him proven management experience, in-depth knowledge of manufacturing systems, development knowledge in immediate and extended release formulations and extensive regulatory experience of GMP and FDA regulations. Prior to his leading Elite, from 2004 to 2013, Mr. Hakim was employed by Actavis, Watson and Alpharma in various senior management positions. Most recently, Mr. Hakim served as International Vice President of Quality Assurance at Actavis, overseeing 25 sites with more than 3,000 employees under his leadership. Mr. Hakim also served as Corporate Vice President of Technical Services, Quality and Regulatory Compliance for Actavis U.S., Global Vice President, Quality and Regulatory Compliance for Alpharma, as well as Executive Director of Quality Unit at TheraTech, overseeing manufacturing and research and development. In 2009, Mr. Hakim founded Mikah Pharma, LLC, a virtual, fully functional pharmaceutical company.

Mr. Hakim’s career started in Medical Laboratory Technology from the Academy of Health and Sciences in the U.S. Army based in San Antonio, TX, followed by Graduate Certification in Regulatory Affairs (RAC) from California State University at Sacramento, Sacramento, CA; Bachelor in Chemistry/Bio-Chemistry and Masters of Science in Chemistry from California State University at Sacramento, Sacramento, CA; and a Masters in Law with Graduate Certification in U.S. Taxation from St. Thomas University, School of Law, Miami, FL.

Board of Directors Chairman - Jerry Treppel

Mr. Treppel is currently a Managing Director of ArcLight Advisors, an investment bank specializing in the health care sector. From October 2008 through March 2013, Mr. Treppel was Managing Director of Ledgemont Capital Group LLC, a boutique merchant bank that provided access to capital and corporate advisory services to public and private companies. Additionally, he served as the managing member of Wheaten Capital Management LLC, a capital management company focusing on investments in the health care sector from 2003 to 2008. Over the past 20 years, Mr. Treppel was an equity research analyst focusing on the specialty pharmaceuticals and generic drug sectors at several investment banking firms including Banc of America Securities, Warburg Dillon Read LLC (now UBS), and Kidder Peabody and Co. He previously served as a healthcare services analyst at various firms, including Merrill Lynch & Co. Mr. Treppel holds a BA in Biology from Rutgers College, an MHA in Health Administration from Washington University, and an MBA in Finance from New York University. Mr. Treppel has been a Chartered Financial Analyst *CFA) since 1988.

Investor Relations:

Vice President of Investor Relations and Corporate - Dianne Will

Dianne Will joined Elite in 2003 as an Investor Relations Specialist and was named Elite’s Vice President of Investor Relations and Corporate Affairs in 2013. In 1996, Ms. Will founded Willstar Consultants, an investor relations consulting firm and has been providing investor relations services to a range of public companies for more than 19 years with a primary focus in the pharmaceutical and tech sectors. Her firm provides corporate services including management and execution of investor relations programs, investor communication, peer research, compliance services, support for
management team changes, proxy fights, crisis management and IPOs.

Investor Relations and Corporate Inquiries

Dianne Will
Vice President of Investor Relations and Corporate Affairs
Telephone: 518-398-6222

Corporate Headquarters

165 Ludlow Avenue
Northvale, New Jersey 07647
Phone: 201-750-2646
Fax: 201-750-2755

Miscellaneous Links:

SEC Filings:

FDA website:

Clinical Trials.Gov:


  Using the industry average PE\Ratio of 15, an over exaggerated  share count of 100% of the 995M authorized shares, and a very conservative
  profit margin of 30%, Elite stands to garner an increase in share price with the launch of each abuse resistant opioid product.


  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
ELTP News: Initial Statement of Beneficial Ownership (3) 04/25/2016 12:43:52 PM
ELTP News: Statement of Changes in Beneficial Ownership (4) 04/15/2016 03:14:26 PM
ELTP News: Current Report Filing (8-k) 04/12/2016 08:31:16 AM
ELTP News: Statement of Changes in Beneficial Ownership (4) 03/21/2016 05:08:13 PM
ELTP News: Statement of Changes in Beneficial Ownership (4) 02/18/2016 06:45:05 PM
#193807  Sticky Note ELITE PHARMACEUTICAL positioned to capitalize on opiod crisis NASDAQ2020 04/11/16 04:41:02 PM
#189575  Sticky Note 4-REASONS-ELTP-is-in-the-Midst-of-the-Perfect-Storm:-A-GREAT-BUY-NOW: Couch 03/18/16 07:41:32 AM
#189564  Sticky Note $ELTP SequestOx and ADF Patents lasers 03/18/16 04:29:26 AM
#185967  Sticky Note The only topic here is ELTP. IH Admin [Dan] 02/23/16 09:32:46 PM
#182215  Sticky Note With all due respect, everyone keeps talking about Je3232 02/04/16 12:19:02 PM
#180358  Sticky Note Elite delivered every promise they made, sometime bit Dr_Thorfin 01/24/16 09:06:16 AM
#197770 rollin2nyte 05/02/16 03:21:45 AM
#197769   Plus a law degree as well as being mrwrn2010 05/02/16 02:49:20 AM
#197768   Quote- Maybe ELTP executes and maybe this company Dr_Thorfin 05/02/16 01:28:46 AM
#197767   We provide proof day in day out, all Dr_Thorfin 05/02/16 01:12:26 AM
#197766   Continuous references to the fact we aren't at Sixman 05/02/16 01:09:29 AM
#197765   Institutional buyers gobbled up 48% of kmph shares Dr_Thorfin 05/02/16 01:01:27 AM
#197764   Thank god I read this before I went newguy11 05/02/16 01:00:55 AM
#197763   Greenlife, You have no right to call people names. Rebel13 05/02/16 12:21:21 AM
#197762   I'm sorry but you are a f...'in idiot..if greenlife 05/02/16 12:08:16 AM
#197761   agree totally! There might be a little bump jtf3 05/01/16 11:28:09 PM
#197760   $550 million might get them One ADF NASDAQ2020 05/01/16 11:26:53 PM
#197759   Does ELTP being stuck at 32 cents while namtae 05/01/16 11:12:24 PM
#197758   LOL LOL they cant afford elite, my god, dr_lowenstein 05/01/16 10:49:46 PM
#197757   Of course, the reason people invest in ELTP namtae 05/01/16 10:48:38 PM
#197756   Puracap can not afford Elite so they did NASDAQ2020 05/01/16 10:45:59 PM
#197755   who? oh, teva, not even in the top dr_lowenstein 05/01/16 10:43:48 PM
#197754   Puracap can't afford ELITE. No LINK needed. YJ4LIFE 05/01/16 10:36:14 PM
#197753   Yeah but puracrap didn't buy elite did they? dr_lowenstein 05/01/16 10:26:44 PM
#197752   Epic had 15 generics NASDAQ2020 05/01/16 10:16:17 PM
#197751   Teva ran a bunion trial. You know, one mrwrn2010 05/01/16 10:05:53 PM
#197750   A capable researcher, taking a moment, will be no2koolaid 05/01/16 10:02:53 PM
#197749   Exactly how can anyone outside the company answer no2koolaid 05/01/16 09:48:38 PM
#197748   The tyranny of wrong numbers is it not? no2koolaid 05/01/16 09:44:52 PM
#197747   The evidence offered is so compelling as to no2koolaid 05/01/16 09:35:30 PM
#197746   Then why and for what did human well Sixman 05/01/16 09:06:06 PM
#197745   Yeah, for two reasons. Pain medication is worth Chasing 05/01/16 09:03:43 PM
#197744   So Epic gets purchased for 550 million and jtf3 05/01/16 08:51:46 PM
#197743   The wish and hope of all short positions, newguy11 05/01/16 08:42:10 PM
#197742   Can I get you to guarantee ELI-200 doesn't rollin2nyte 05/01/16 08:27:30 PM
#197741   Wow, you forget the Epic acquisition which was rollin2nyte 05/01/16 08:21:58 PM
#197740   Great post, thank you! rollin2nyte 05/01/16 08:21:03 PM
#197739   You make this list up. It's funny. Sixman 05/01/16 08:17:54 PM
#197738   Former 97 cent ELTP down 67% while general namtae 05/01/16 08:08:28 PM
#197737   Eli200 could be the one FDA reject. Puny namtae 05/01/16 07:59:53 PM
#197736   The data is hard to ignore. NASDAQ2020 05/01/16 07:55:53 PM
#197735   Oops ... Mentioned here.. Sorry just more misinformation. Gman24 05/01/16 07:54:22 PM
#197734   I noticed Elite is not mentioned anywhere. Wonder why? richme 05/01/16 07:45:34 PM
#197733   Excellent Post, very informative. NASDAQ2020 05/01/16 07:42:45 PM
#197732   oh oh oh!!! I can, nowhere, no efficacy dr_lowenstein 05/01/16 07:38:04 PM
#197731   well, LOL LOL I have a chemistry background dr_lowenstein 05/01/16 07:36:10 PM
#197730   For anyone without a Chemisrty background here is NASDAQ2020 05/01/16 07:29:25 PM
#197729   small problem, no data t0 support any of dr_lowenstein 05/01/16 07:22:26 PM
#197728   Correct SeequesrOx will reduce new users from becoming NASDAQ2020 05/01/16 07:20:18 PM
#197727   Correct new user will not be able to NASDAQ2020 05/01/16 07:13:41 PM
#197726   Nah, thats the reason ELTP is no longer namtae 05/01/16 07:07:27 PM
#197725   That's exactly why we are not a 4¢ anymore. NASDAQ2020 05/01/16 07:03:48 PM
#197724   32 cent penny stock that cant secure traditional, namtae 05/01/16 06:57:20 PM
#197723   Was that before they said nit even the dr_lowenstein 05/01/16 06:52:54 PM
#197722   Thank you for that opinion dr_lowenstein 05/01/16 06:51:50 PM
#197721   This REPOST says ELTP knows exactly what they Gman24 05/01/16 06:48:32 PM